|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 01/09/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 01/01/2023 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 04/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 26/08/2016 |
Günter von Au
CHM | Chairman | 75 | 27/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| +1.26% | -2.29% | +36.97% | +104.79% | 1,032B | ||
| +0.73% | -4.78% | +35.41% | +61.62% | 614B | ||
| +0.35% | +1.29% | +15.86% | +79.90% | 471B | ||
| +1.72% | -4.92% | +59.84% | +36.64% | 350B | ||
| +1.72% | +1.69% | +23.05% | +41.52% | 337B | ||
| +1.28% | -1.20% | +12.70% | +34.48% | 268B | ||
| +0.52% | -2.24% | -6.06% | +10.59% | 246B | ||
| -0.09% | -4.97% | +36.88% | +50.52% | 218B | ||
| -0.28% | -4.66% | +26.99% | +92.98% | 179B | ||
| Average | +0.43% | -3.24% | +26.85% | +57.00% | 372.06B | |
| Weighted average by Cap. | +0.57% | -3.18% | +29.84% | +67.27% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















